INTRODUCTION
Some patients with unexplained viral pneumonia were reported in Wuhan, a
city in the Hubei Province of China, at the end of 2019. Following its
identification as a novel coronavirus pathogen (SARS-CoV-2) and an
increasing number of cases in many countries, especially in Europe,
World Health Organization (WHO) declared the COVID-19 as a pandemic on
March 11, 2020.1 In this process, many data show that
COVID-19 should be considered as a systemic disease, including
respiratory, neuromuscular, cardiovascular, dermatological, immune and
hematological systems.2,3 Therefore, in addition to
treatment guidelines of COVID-19, various management guidelines related
to specific divisions have been published from diverse societies and
centers.4-6
Some studies reported that patients who were diagnosed with cancer and
also immunosuppressed have a significantly higher risk of infection with
SARS-CoV-2.7,8 Although the infection does not have
any specific clinical findings, several hematological findings, such as
lymphopenia, thrombocytopenia, prolonged coagulation tests, increased
fibrin degradation products and increased ferritin levels, were also
defined in patients who are virus-infected.5
To our knowledge, there was no study evaluated hematology consultation
in the COVID-19 era in the literature. Herein, we aimed to present
features of patients who consulted the hematology unit in this term.